









Markets
/
Stocks
/
nasdaq-twst
/

Twist Bioscience Corp

TWST

49.240USD

+2.140+4.54%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.02BMarket Cap

LossP/E TTM



Twist Bioscience Corp

49.240

+2.140+4.54%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Twist Bioscience Corp

Currency: USD Updated: 2026-02-06

Key Insights

Twist Bioscience Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 19 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.60.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Twist Bioscience Corp's Score

Industry at a Glance

Industry Ranking

19 / 159

Overall Ranking

62 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Twist Bioscience Corp Highlights

StrengthsRisks

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 53.63% year-on-year.

Undervalued

The company’s latest PE is -38.95, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 73.84M shares, decreasing 3.89% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 16.00K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.78.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

50.600

Target Price

+7.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Twist Bioscience Corp is 8.16, ranking 81 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 103.70M, representing a year-over-year increase of 16.89%, while its net profit experienced a year-over-year increase of 3.44%.

Score

Industry at a Glance

Previous score

8.16

Change



Financials

8.35

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.99

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.31

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Twist Bioscience Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Twist Bioscience Corp is 7.58, ranking 62 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -38.95, which is -92.18% below the recent high of -3.05 and 0.00% above the recent low of -38.95.

Score

Industry at a Glance

Previous score

7.58

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 19/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Twist Bioscience Corp is 8.55, ranking 29 out of 159 in the Pharmaceuticals industry. The average price target is 36.00, with a high of 57.17 and a low of 32.00.

Score

Industry at a Glance

Previous score

8.55

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

50.600

Target Price

+5.15%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Twist Bioscience Corp

TWST

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Twist Bioscience Corp is 9.71, ranking 7 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 54.35 and the support level at 39.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.58

Change

0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.774

Buy

RSI(14)

72.605

Buy

STOCH(KDJ)(9,3,3)

88.575

Overbought

ATR(14)

2.790

Low Volatility

CCI(14)

137.045

Buy

Williams %R

4.533

Overbought

TRIX(12,20)

1.190

Sell

StochRSI(14)

84.484

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

47.518

Buy

MA10

44.731

Buy

MA20

42.850

Buy

MA50

36.664

Buy

MA100

33.298

Buy

MA200

32.722

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Twist Bioscience Corp is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 120.43%, representing a quarter-over-quarter increase of 1.13%. The largest institutional shareholder is Catherine Wood, holding a total of 7.56M shares, representing 12.33% of shares outstanding, with 18.36% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

6.73M

+5.10%

Artisan Partners Limited Partnership

6.41M

+26.67%

The Vanguard Group, Inc.

Star Investors

5.76M

-1.09%

BlackRock Institutional Trust Company, N.A.

4.81M

-0.95%

William Blair Investment Management, LLC

4.14M

+6.03%

EdgePoint Investment Group Inc.

Star Investors

4.08M

+71.10%

State Street Investment Management (US)

3.09M

+23.51%

Amova Asset Management Co., Ltd.

2.12M

-7.79%

Soleus Capital Management, L.P.

1.87M

+426.59%

Millennium Management LLC

1.79M

+151.55%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Twist Bioscience Corp is 4.71, ranking 85 out of 159 in the Pharmaceuticals industry. The company's beta value is 2.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.